-
Forest's deal with Trevena gives the specialty pharma access to a lead compound in acute heart failure that is based on a proven target and helps the biotech build out its biased ligand platform.
Published on 5/13/2013
-
BMS is proving its HCV ambitions did not die with Inhibitex's INX-189. Its next choice for all-oral regimen - an NS5A, NS3 and non-nuc triple combination - achieved competitive SVR rates in a Phase IIa trial.
Published on 4/29/2013
-
Genentech has a portfolio of compounds that could allow it to hit different targets in the PI3K pathway for a variety of solid cancers.
Published on 4/15/2013
-
The big series A round for GenSight reflects the investors' confidence that gene therapies for the eye can be brought to market quickly and at reasonable cost.
Published on 4/15/2013
-
Otsuka's deal with H. Lundbeck gives the Japanese pharma a piece of the most advanced serotonin (5-HT6) receptor antagonist to treat the cognitive symptoms of Alzheimer's disease.
Published on 4/8/2013
-
Novo Nordisk thinks a growing data package for 3 mg liraglutide will clear FDA's regulatory hurdles to treat obesity in patients with diabetes and other co-morbidities.
Published on 4/8/2013
-
In the spirit of April Fools, biotech bloopers discovered by BioCentury editors.
Published on 4/1/2013
-
Tetragenetics is unveiling deals with Amgen and Pfizer to produce proteins for antibody screens that would be difficult to make in standard protein expression systems.
Published on 4/1/2013
-
While many homegrown biologics in China could be perceived as biosimilars, most are unlikely to meet international standards. Henlius and Innovent are two companies hoping to change that.
Published on 3/18/2013
-
South Korea's Neomics is leveraging previously unknown functions of aminoacyl tRNA synthetases to develop therapeutics and diagnostics for cancer.
Published on 3/11/2013
-
Despite other CETP inhibitor failures, Dezima believes its DEZ-001 can improve CV outcomes based on best-in-class reductions in LDL and lipoprotein(a).
Published on 1/28/2013
-
Dissecting the Phase III failure of Biogen Idec's dexpramipexole, three Phase II players say they have identified strategies to improve the odds of clinical success in amyotrophic lateral sclerosis.
Published on 1/21/2013
-
Phase I data for Bind Biosciences' nanotechnology particle in cancer demonstrated sufficient POC for the biotech to snag Amgen as a partner for the technology.
Published on 1/21/2013
-
Solving the ALS maze ALS pipeline At least 12 therapies for amyotrophic lateral sclerosis (ALS) are in or about to start clinical testing. The therapies range from neuroprotectants and neurotrophic factors to muscle…
Published on 1/21/2013
-
Forward Pharma is developing a controlled-release fumarate that may be more tolerable than Biogen Idec's BG-12. But the Nordic biotech is starting with psoriasis instead of MS.
Published on 1/7/2013
-
In vitro and in vivo data show Nimbus' IRAK4 inhibitors could help treat mutation-defined subtypes of B cell lymphomas and hematological cancers.
Published on 12/24/2012
-
Proof-of-concept data in cancer for Arrowhead's peptide-based tissue targeting platform were good enough to get Shire to try it out in rare diseases, where getting therapies to the right tissues can be a challenge.
Published on 12/24/2012
-
Despite the failure of the first compound using its Lipid Vector technology, Clavis believes its second shot on goal could still succeed in Phase III because of a significant PK advantage over the parent drug.
Published on 11/19/2012
-
Amgen's AMG 145 may be six to nine months behind the lead anti-PCSK9 mAb, but the company hopes to counter this potential first-mover advantage by offering a monthly dosing option.
Published on 11/12/2012
-
Omthera's Phase III data for Epanova suggest the omega-3 fatty acid product could compete with approved lipid-lowering drugs Lovaza from GSK/Pronova and Vascepa from Amarin.
Published on 11/12/2012
-
Piecing together PCSK9 PCSK9 data comps Phase II proof-of-concept data presented at last week's American Heart Association meeting in Los Angeles provide further evidence to support the safety and efficacy of the …
Published on 11/12/2012
-
Physicians say data for Biogen Idec's long-acting rFVIIIFc could motivate about 15% of hemophilia A patients to switch treatments. Long-term data may be needed to convert a larger population
Published on 11/12/2012
-
NIH and industry have spent the past year discussing target validation; now pilot projects must be developed if aspirations for a precompetitive consortium are to bear fruit.
Published on 11/5/2012
-
The decision to enroll sicker CKD patients in Phase III trials of bardoxolone might have amplified safety signals seen in Phase II, and put the future of Reata's AIM portfolio in jeopardy.
Published on 10/29/2012
-
Reata, AIM, backfire Bardoxolone's bad side There were red flags in the Phase IIb BEAM trial that Reata Pharmaceutical Inc.'s bardoxolone may have been harming patients with chronic kidney disease, according to four…
Published on 10/29/2012